Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas-Reference-Cited by-同舟云学术

Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas

Published:2016-08-17 Issue:11 Volume:39 Page:1073-1091
ISSN:0114-5916
Container-title:Drug Safety
language:en
Short-container-title:Drug Saf

Author:

Shah Rashmi R.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Toxicology

Link

http://link.springer.com/content/pdf/10.1007/s40264-016-0450-9.pdf

Reference144 articles.

1. Food and Drug Administration. Approval letter for tofacitinib (XELJANZ) (NDA 203214) (6 November 2012). Available at: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/203214Orig1s000ltr.pdf . Accessed on 21 July 2016.

2. Food and Drug Administration. Approval letter for nintedanib (OFEV) (NDA 205832) (15 October 2014). Available at: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/205832Orig1s000ltr.pdf . Accessed on 21 July 2016.

3. European Medicines Agency. Approval of nintedanib (VARGATEF) for NSCLC (21 November 2014). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002569/WC500173607.pdf .Accessed on 21 July 2016.

4. European Medicines Agency. Refusal of the marketing authorisation for XELJANZ (tofacitinib) (26 April 2013) (EMA/248755/2013; EMEA/H/C/002542). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002542/WC500142485.pdf . Accessed on 21 July 2016.

5. Rask-Andersen M, Zhang J, Fabbro D, Schiöth HB. Advances in kinase targeting: current clinical use and clinical trials. Trends Pharmacol Sci. 2014;35:604–20.

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interstitial Pneumonitis Following Sequential Administration of Programmed Death-1/Programmed Death-Ligand1 Inhibitors and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors For Non-Small Cell Lung Cancer: A Matched‐Pair Cohort Study Using a Nationwide Inpatient Database;Clinical Lung Cancer;2024-09

2. A real-world pharmacovigilance study of KRAS G12C mutation inhibitors based on the food and drug administration adverse event reporting system;Frontiers in Pharmacology;2024-08-28

3. Trastuzumab-deruxtecan in solid tumors with HER2 alterations: from early phase development to the first agnostic approval of an antibody–drug conjugate;Expert Opinion on Investigational Drugs;2024-07-09

4. Treatment dilemmas in patients with gastrointestinal stromal tumors (GIST) who experienced imatinib-induced pneumonitis: A case series;Current Problems in Cancer: Case Reports;2024-03

5. Combination of Anti-Angiogenics and Immunotherapies in Renal Cell Carcinoma Show Their Limits: Targeting Fibrosis to Break through the Glass Ceiling?;Biomedicines;2024-02-07